Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature

References

• Mendiratta V, Jabeen M. Infantile hemangioma: an update. Indian J Dermatol Venerol Leprol 2010;76:469–75
   PubMed Web of Science ®Google Scholar
• Vlastarakos PV, Papacharalampous GX, Chrysostomou M, et al. Propranolol is an effective treatment for airway haemengiomas: a critical analysis and meta-analysis of published interventional studies. Acta Otorhinolaryngol 2012;32:213–21
   Google Scholar
• Drolet BA, Swanson EA, Froeden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008;153:712–15
   PubMed Web of Science ®Google Scholar
• Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007;150:291–4
   PubMed Web of Science ®Google Scholar
• Starkey E, Shahidullah H. Propranolol for infantile hemangiomas: a review. Arch Dis Child 2011;96:890–3
   PubMed Web of Science ®Google Scholar
• Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics 2013;131:99–108
   PubMed Web of Science ®Google Scholar
• Frieden IJ, Haggstrom AN, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7–9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005;22:383–406
   PubMedGoogle Scholar
• Chakkittakandiyil A, Phillips R, Frieden I, et al. Timolol maleate 0,5% or 0,1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012;29:28–31
   PubMed Web of Science ®Google Scholar
• Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124:423–31
   PubMed Web of Science ®Google Scholar
• Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg 2010;29:106–14
   PubMed Web of Science ®Google Scholar
• Oranje AP, Janmohamed SR, Madern GC, et al. Treatment of small superficial haemangioma with timolol 0,5% ophthalmic solution: a series of 20 cases. Dermatology 2011;223:330–4
   PubMed Web of Science ®Google Scholar
• Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents’ photographs tell us. Pediatrics 2012;130:314–20
   PubMed Web of Science ®Google Scholar
• North PE, Waner M, Mizeracki A, et al. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000;31:11–22
   PubMed Web of Science ®Google Scholar
• Mihm MC Jr, Nelson JS. Hypothesis: the metastatic niche theory can elucidate infantile hemangioma development. J Cutan Pathol 2010;37:83–7
   PubMed Web of Science ®Google Scholar
• Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Genes Chromosomes Cancer 2002;33:295–303
   PubMed Web of Science ®Google Scholar
• Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008;118:2592–9
   PubMed Web of Science ®Google Scholar
• Drolet BA, Frieden IJ. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Arch Dermatol 2010;146:1295–9
   PubMed Web of Science ®Google Scholar
• Greenberger S, Boscolo E, Adini I, et al. Corticosteriod suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010;362:1005–13
   PubMed Web of Science ®Google Scholar
• Ritter MR, Dorrell MI, Edmonds J, et al. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 2002;99:7455–60
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Tepper OM, Capla JM, et al. Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma. Lymphat Res Biol 2003;1:301–7
   PubMedGoogle Scholar
• Lee KC, Bercovitch L. Update on infantile hemangiomas. Semin Perinatol 2013;37:49–58
   PubMed Web of Science ®Google Scholar
• Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649–51
   PubMed Web of Science ®Google Scholar
• Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol 2010;162:466–8
   PubMed Web of Science ®Google Scholar
• Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr 2011;170:493–501
   PubMed Web of Science ®Google Scholar
• Price CJ, lattout C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol 2011;147:1371–6
   PubMed Web of Science ®Google Scholar
• Hsu TC, Wang JD, Chen CH, et al. Treatment with propranolol for infantile hemangioma in 13 taiwanese newborns and young infants. Pediatr Neonatol 2012;53:125–32
   PubMed Web of Science ®Google Scholar
• Holmes W, Mishra A, Gorst C, et al. Propranolol as first-line treatment for rapidly proliferating infantile hemangiomas. J Plast Reconstr Aesthet Surg 2011;64:445–51
   PubMed Web of Science ®Google Scholar
• Sarialioglu F, Erbay A, Demir S. Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy. Pediatr Blood Cancer 2010;55:1433–4
   PubMed Web of Science ®Google Scholar
• Marsciani A, Pericoli R, Alaggio R, et al. Massive response of severe infantile hepatic hemangioma to propranolol. Pediatr Blood Cancer 2010;54:176
   PubMed Web of Science ®Google Scholar
• Holland KE, Frieden IJ, Frommelt PC, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010;146:775–8
   PubMed Web of Science ®Google Scholar
• Chiller KG, Passarro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002;138:1567–76
   PubMed Web of Science ®Google Scholar
• Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001;44:962–72
   PubMed Web of Science ®Google Scholar
• Erbay A, Sarialioglu F, Malbora B, et al. Propranolol for infantile hemangiomas: a preliminary report on efficacy and safety in very low birth weight infants. Turk J Pediatr 2010;52:450–6
   PubMed Web of Science ®Google Scholar
• Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004;350:1304–13
   PubMed Web of Science ®Google Scholar
• Spiteri Cornish K, Reddy AR. The use of propranolol in the management of periocular capillary haemangioma – a systematic review. Eye 2011;25:1277–83
   PubMed Web of Science ®Google Scholar
• Leboulanger N, Fayoux P, Teissier N, et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: a preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol 2010;11:1254–7
   Web of Science ®Google Scholar
• Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003;48:477–93
   PubMed Web of Science ®Google Scholar
• Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010;128:255–6
   PubMed Web of Science ®Google Scholar
• Moehrle M, Leaute-Labreze C, Schmidt V, et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2012;30:245–9
   PubMed Web of Science ®Google Scholar
• Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010;146:564–5
   PubMed Web of Science ®Google Scholar